The Filing Desk

Taysha Gene Therapies

TSHA · Nasdaq · Health Care · Financials, fiscal 2020 to 2025

TSHA · Last close · November 13, 2026
$4.10
Value Taysha Gene Therapies yourself

Taysha Gene Therapies' revenue rose 17.3% to $10 million in fiscal 2025. Its operating margin was −1,130.7%, down from −1,097.5% a year earlier. Free cash flow was −$94 million. The diluted share count rose 27.8%.

Taysha Gene Therapies, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 19, 2026 · 0001193125-26-115202 Updated
Revenue
$10M
17.3%
Operating margin
−1,130.7%
33.1 pts
Net income
−$109M
 
Free cash flow
−$94M
 
Return on equity
−68.5%
53.5 pts
Market cap
$1.7B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Taysha Gene Therapies does

Taysha Gene Therapies is a clinical-stage biotechnology company. It develops gene therapies, built on a harmless virus called AAV, for severe single-gene diseases of the central nervous system. A gene therapy delivers a working copy of a gene into a patient's cells. The company has no approved products.

Its lead program, TSHA-102, is for Rett syndrome, a rare neurodevelopmental disorder caused by mutations in the MECP2 gene. TSHA-102 is meant as a one-time treatment given by injection into the spinal fluid. It is being tested in the REVEAL trials and in a smaller safety study called ASPIRE. The company says it has written agreement with the FDA on the design of its pivotal trial and on the data for a planned application to market the drug. The first patient in the pivotal trial was dosed in the fourth quarter of 2025. The FDA has given the drug several special designations, including orphan drug and Fast Track.

Because it has nothing to sell yet, the company funds itself from outside money. It also relies on a collaboration with UT Southwestern for its early research programs and on contract manufacturers for the AAV9 material.

Its biggest risks, as it describes them

  • Losses since it began, with no assurance it will ever be profitable.
  • Needing substantial additional funding, or having to cut back its plans.
  • No product tested to completion in clinical trials, and no history of selling products.
  • Reliance on third-party manufacturers of its AAV9 gene therapy, which face heavy regulation.
  • Reliance on UT Southwestern for its early research, and strong competition from other biotechnology and pharmaceutical companies.
From Taysha Gene Therapies's annual report on Form 10-K, filed March 19, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Taysha Gene Therapies lost money in fiscal 2025: a net loss of $109 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments14988144139320
Debt incl. finance leases3739424550
Net debt (negative means net cash)−112−49−102−94−269
Net debt to EBITDA—————
Debt to equity0.4x—0.6x0.6x0.2x
Interest coverage−121.3x−42.8x−14.5x−896.7x−1,753.9x
Current ratio3.1x1.5x4.1x5.4x12.2x
Quick ratio3.1x1.5x4.1x5.4x12.2x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Taysha Gene Therapies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Taysha Gene Therapies reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score3 of 84 of 84 of 8
Rule of 4019.9%−1,025.3%−942.8%
Altman Z''−7.40−10.49−0.53
Accruals ratio−25.8%−4.8%−6.3%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassFailPass
F-score3 of 84 of 84 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Taysha Gene Therapies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Taysha Gene TherapiesFY2517.3%−1,130.7%−960.1%——4
Janux TherapeuticsFY25−5.5%−1,576.7%−832.8%———Compare
Roivant SciencesFY25−71.6%−6,235.7%−9,183.5%−62.6%—1Compare
Arbutus BiopharmaFY25128.2%−271.0%−281.4%——3Compare
Relay TherapeuticsFY2553.4%−1,971.6%−1,536.1%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

6 years of figures

Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Revenue——216810
Revenue growth———517.5%−46.1%17.3%
Gross profit——————
Research and development3213291576686
Operating income−43−173−162−72−92−110
Net income−60−174−166−112−89−109
Diluted EPS (US$)−3.40−4.64−3.78−0.96−0.36−0.34
Diluted shares (millions)183844116250320
Cash flow
Cash from operations−31−117−88−73−81−93
Capital expenditure01521401
Free cash flow−31−132−109−77−82−94
Dividends paid000000
Share buybacks000000
Acquisitions000000
Stock-based compensation3181881313
Balance sheet at fiscal year end
Cash and short-term investments25114988144139320
Debt incl. finance leases—3739424550
Total assets259214126173160343
Total liabilities8119125988996
Shareholders' equity2519517572247
Margins and ratios
Gross margin——————
Operating margin——−6,492.7%−468.8%−1,097.5%−1,130.7%
Net margin——−6,635.2%−722.1%−1,071.6%−1,115.3%
Free cash flow margin——−4,356.9%−497.6%−979.2%−960.1%
Rule of 40 (growth + FCF margin)———19.9%−1,025.3%−942.8%
Return on capital——————
Return on equity—−100.7%−344.7%−294.0%−121.9%−68.5%
Return on assets—−73.8%−97.6%−74.6%−53.6%−43.3%
Net debt to EBITDA——————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Taysha Gene Therapies' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Taysha Gene Therapies.